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The sustained virological response (SVR) of the com-
bination of both pegylated interferon alfa (PegIFN) and 
ribavirin (RBV) in patients with chronic hepatitis C virus 
(HCV) infection is heterogeneous.
1 The therapeutic approach 
has been more individualized to obtain the better outcomes 
of patients with chronic HCV infection, and clinicians need 
to know the factors for predicting SVR.
2 The viral factors are 
HCV genotype and serum HCV RNA levels at baseline, and 
numerous host factors include age, sex, race, weight, liver 
fibrosis, and insulin resistance.
1 Recently, an interleukin-28 
polymorphism has been acknowledged as powerful pretrea-
tment predictor of SVR.
3,4 
Once treatment is initiated, the monitoring of on- 
treatment viral responses such as rapid virological response 
(RVR) and early virological response (EVR) can further aid 
in predicting treatment response.
5 However, there was little 
data evaluated the relationship between on-treatment ALT 
changes and therapeutic outcome of PegIFN and RBV in 
chronic HCV. Kim et al
6 reported interesting evidence 
showing that the rapid normalization of serum ALT after 
start of treatment may play an additional role on predicting 
SVR.
Serum ALT levels are usually elevated in patients with 
chronic HCV, but more than half of patients may have a 
normal ALT level at some point due to its fluctuation.
7 In 
patients with persistently normal ALT levels, the median 
ALT levels remains stable for prolonged period, but 
transient elevations occur about 50% of cases.
8 Sustained 
normal serum ALT levels were associated with female, 
lower serum HCV RNA titer, and less inflammation and 
fibrosis on biopsy.
8 During chronic infection, serum HCV 
RNA levels remain relatively constant without significant 
fluctuation in untreated individuals.
9 This suggests that the 
process of viral production and clearance has been relatively 
balanced. 
To investigate the effect ALT dynamics on SVR, we need 
to know the relationship with viral kinetics. Viral kinetic 
profiles show that the appearance of HCV RNA after 
initiation of standard therapy can be biphasic in the first 4 
weeks.
10,11 The final slope reflects the net loss of infected 
cells, and a rapid loss of infected cells is strongly associated 
with end treatment of response and SVR.
12,13 Serum ALT, a 
surrogate marker of hepatocyte damage or death, decreases 
during antiviral treatment, and shows the lowest activity at 
the end of treatment.
14 The mechanism of decline of ALT 
level is not clear, but it can be explained by a reduction 
in infected cells, a non-cytolytic cure, or cell removal 30  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
irrelevant ALT dynamics. However, a decreased ALT level 
at early phase of treatment is not related with apoptotic 
acitivity.
15 Theoretically, the rapid declines in ALT may 
reflect a rapid decrease of ongoing inflammation in the 
same manner as removal of the virus. The pattern of viral 
elimination shows a rapid decrease in the first month. 
Ribeiro et al
14 showed that the RVR was significantly 
correlated the decline of ALT level at week 4 of treatment. 
Also, the retrospective study of 111 patients with chronic 
HCV infection treated by conventional IFN and RBV 
demonstrated that larger decline rates of ALT within the 
first two and four weeks was predictors of SVR.
16 These 
correlations suggest that ALT dynamics can be presented a 
possibility to reflect rapid virological changes especially in 
patients with elevated baseline ALT levels. 
Kim et al
6 retrospectively analyzed changes in ALT levels 
between baseline and week 4 of treatment in 168 patients 
with chronic HCV infection. Multivariate analysis in this 
study showed that genotype, baseline viral load, age and 
ALT changes during antiviral therapy were independent 
predictors of SVR. These factors are in good agreement with 
recent data. This study has three interesting points. First, 
rapid normalization of ALT within 1.5 times of normal range 
after treatment significantly was associated with improved 
SVR in genotype I HCV patients (34.1% versus 20.0%, 
P=0.01) and non-1 HCV patients (88.1% versus 66.7%, 
P=0.11) who had initially high ALT levels. Currently, the 
monitoring of on-treatment viral responses such as RVR or 
EVR is important in treatment of chronic HCV infection 
for predicting the therapeutic response and determining 
discontinuation of therapy.
1 As mentioned above, a rapid 
decreases of ALT may reflect declines of viral load, and this 
result suggests that rapid normalization of ALT at week 4 of 
treatment could be used as a strategy for predicting a 
response of early viral load quantification in patients with 
high baseline ALT levels. 
Second, 37/113 (32.7%) of patients with elevated baseline 
ALT levels had remained high ALT levels and 15/55 
(27.3%) of patients with normal range of baseline ALT 
levels experienced high ALT during treatment. These groups 
had a low probability of SVR. Similar to this result, recent 
report suggested that mild ALT elevations (peak ALT value 
1-1.5 x baseline value) during treatment may reflect ongoing 
viral activity in non-responders, but more significant rise 
may reflect a good virological response due to an immune- 
modulating effect of interferon.
17 However, this data was 
difficult to analyze the reason of on-treatment ALT elevation 
and to elucidate the relationship between on-treatment ALT 
elevation and SVR. 
Third, previous study showed that SVR rates of the 
standard therapy in patients with normal ALT had relatively 
high, and were comparable with those with elevated ALT.
18 
In the present study, 55/168 (32.7%) of enrolled patients had 
baseline normal range of ALT, and 40/55(72.7%) of these 
patients with sustained normal range of ALT had a high 
SVR rates (77.5%). Again, this result confirmed that the 
therapeutic response of the interferon-based regimen was 
not different between patients with normal ALT and 
elevated ALT 
This study has several limitations of retrospective design, 
smaller group, and absence of potential confounders. Rapid 
normalization of ALT was used for predicting SVR in 
patients with elevated baseline ALT levels, but its usefulness 
is limited because of the paucity of knowledge about RVR 
and the difficulty of application in normal ALT levels. 
Because RVR is the most important predictor of SVR in 
genotype 2 or 3 infection, it is unreasonable to apply this 
result for predicting SVR except for genotype 1 infection. 
Therefore, it is still unclear whether the use of serum ALT 
levels, instead of RVR, is helpful for predicting SVR in 
clinical practice. 
In conclusion, this study showed that the rapid decline of 
ALT at week 4 of treatment is linked to SVR. To date, there 
is little data in relationship between ALT variability and 
SVR in chronic HCV infection. Therefore, such information 
predicting virological response may be useful to clinicians 
for designing a monitoring schedule, and counseling the 
future plan especially in patients with elevated baseline ALT 
levels and genotype 1 infection. Further well designed 
research is needed to test and confirm these concepts.
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